Successful desensitization of trimethoprim-sulfamethoxazole in Stenostrophomonas maltophilia osteomyelitis.
10.4168/aard.2014.2.3.218
- Author:
Sujeong KIM
1
;
Kyung Hwan LIM
;
Min Gyu KANG
;
Han Ki PARK
;
Sang Heon CHO
;
Kyung Up MIN
;
Sae Hoon KIM
;
Yoon Seok CHANG
Author Information
1. Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea. addchang@snu.ac.kr
- Publication Type:Case Report
- Keywords:
Immunologic desensitization;
Hypersensitivity;
Stenotrophomonas maltophilia;
Trimethoprim-sulfamethoxazole combination
- MeSH:
Anti-Infective Agents;
Desensitization, Immunologic;
Humans;
Hypersensitivity;
Hypersensitivity, Delayed;
Mortality;
Osteomyelitis*;
Rare Diseases;
Stenotrophomonas maltophilia;
Trimethoprim, Sulfamethoxazole Drug Combination*
- From:Allergy, Asthma & Respiratory Disease
2014;2(3):218-221
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Stenotrophomonas maltophilia is an emerging pathogen associated with morbidity and mortality in hospitalized patients. The treatment of S. maltophilia infection is challenging because clinical isolates are frequently resistant to most antimicrobial agents except trimethoprim-sulfamethoxazole (TMP-SMX). S. maltophilia osteomyelitis is a rare disease and requires a prolonged treatment with TMP-SMX. Here, we report an interesting case of a patient with S. maltophilia osteomyelitis who developed a delayed hypersensitivity reaction during TMP-SMX treatment and successfully treated after desensitization. TMP-SMX desensitization should be considered in patients with hypersensitivity to TMP-SMX, especially when there are no effective alternative drugs in S. maltophilia infection.
